PAVmed Inc. (NASDAQ: PAVM)

PAVmed is a diversified commercial stage life sciences company with operations in medical device development diagnostics and digital health. The firm advances and commercializes innovative healthcare technologies through its subsidiaries while maintaining flexibility to structure financing at either the corporate level or within each subsidiary. Its primary subsidiaries are Lucid Diagnostics which focuses on cancer prevention diagnostics and Veris Health which concentrates on digital health solutions for oncology care. PAVmed leverages a shared services model to provide common administrative and operational support to its independently financed businesses. This structure enables the company to pursue growth opportunities across multiple healthcare sectors while maintaining distinct strategic initiatives for each segment.

PAVmed generates revenue from the sale of its diagnostic products and services and from subscription fees for its digital health platform. Lucid Diagnostics sells the EsoGuard esophageal DNA test performed with the EsoCheck cell collection device to healthcare providers and receives payments from commercial insurers government programs and direct patient channels. The company also earns revenue through cash pay arrangements and partnerships with telemedicine providers that facilitate direct to consumer access to its testing services. Veris Health offers a software as a service model where hospitals and oncology practices pay monthly fees for each patient enrolled on the Veris Cancer Care Platform to access remote physiological monitoring symptom reporting and telehealth capabilities. Additional revenue may arise from future sales of the implantable physiological monitor that Veris is developing to complement its digital platform.

The company operates through the following segments: Lucid Diagnostics and Veris Health. Each segment is managed as an independent business with its own financing product development and commercialization efforts while benefiting from centralized shared services.

• Lucid Diagnostics: This segment develops and commercializes the EsoGuard esophageal DNA test and the EsoCheck cell collection device for early detection of Barrett's esophagus and esophageal adenocarcinoma in patients with gastroesophageal reflux disease.

• Veris Health: This segment provides a digital cancer care platform that enables remote physiological monitoring symptom reporting and telehealth for oncology patients and is developing an implantable physiological monitor to complement the platform.

In the diagnostics space Lucid Diagnostics faces competition from traditional endoscopic procedures and other biomarker based tests but differentiates itself with its FDA cleared EsoCheck device and its EsoGuard test which has received breakthrough device designation and demonstrates high sensitivity and specificity for detecting esophageal precancer. The company’s diagnostic offering addresses a large underserved market of patients with gastroesophageal reflux disease who are at risk of esophageal cancer but currently undergo low rates of screening. Veris Health competes with other digital health platforms that offer remote patient monitoring and electronic health record integration but distinguishes itself through its focus on oncology survivorship and its upcoming implantable monitor that can provide continuous physiologic data independent of patient compliance. Both subsidiaries benefit from proprietary patent portfolios and strategic partnerships with major health systems and government agencies which support market adoption and reimbursement efforts. These advantages help PAVmed maintain a competitive position despite the presence of larger well capitalized rivals.

Lucid Diagnostics serves gastroenterology physicians primary care providers health systems self insured employers unions and has arrangements with partners such as UpScript LLC and has secured coverage agreements with Highmark Blue Cross Blue Shield and a contract with the US Department of Veterans Affairs. The diagnostic product is also offered through outpatient clinics and physician office networks that seek a noninvasive testing option for Barrett's esophagus. Veris Health works with oncology practices and hospitals including the Ohio State University Comprehensive Cancer Center also known as The James and seeks similar partnerships with other academic oncology institutions. The digital platform is used by cancer care teams to monitor patients during treatment and throughout survivorship supporting timely intervention and improved care coordination. Both businesses target healthcare providers that value innovative tools designed to enhance patient outcomes and reduce overall treatment costs.